Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Respir Med ; 188: 106619, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34555702

RESUMO

BACKGROUND: Invasive fungal infections (IFI) are increasing in prevalence in recent years. In the last few months, the rise of COVID-19 patients has generated a new escalation in patients presenting opportunistic mycoses, mainly by Aspergillus. Candida infections are not being reported yet. OBJECTIVES: We aimed to determine the prevalence of systemic candidiasis in patients admitted to ICUs due to severe pneumonia secondary to SARS-CoV-2 infection and the existence of possible associated risk factors that led these patients to develop candidiasis. PATIENTS/METHODS: We designed a study including patients with a confirmed diagnosis of COVID-19. RESULTS: The prevalence of systemic candidiasis was 14.4%, and the main isolated species were C. albicans and C. parapsilosis. All patients that were tested positive for Candida spp. stayed longer in the ICU in comparison to patients who tested negative. Patients with candidiasis had higher MuLBSTA score and mortality rates and a worse radiological involvement. In our study, Candida spp. isolates were found in patients that were submitted to: tocilizumab, tocilizumab plus systemic steroids, interferon type 1ß and Lopinavir-Ritonavir. CONCLUSIONS: Results suggested a high prevalence of systemic candidiasis in severe COVID-19-associated pneumonia patients. Patients with Candidiasis had the worst clinical outcomes. Treatment with tocilizumab could potentialize the risk to develop systemic candidiasis.


Assuntos
COVID-19/complicações , Candidíase/epidemiologia , Coinfecção/epidemiologia , Pneumonia/epidemiologia , Idoso , COVID-19/diagnóstico , Candida albicans , Candida parapsilosis , Candidíase/complicações , Candidíase/diagnóstico , Coinfecção/diagnóstico , Cuidados Críticos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia/microbiologia , Pneumonia/virologia , Prevalência , Estudos Prospectivos , Fatores de Risco
2.
Mycoses ; 64(2): 144-151, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33217071

RESUMO

BACKGROUND: As the global coronavirus pandemic (COVID-19) spreads across the world, new clinical challenges emerge in the hospital landscape. Among these challenges, the increased risk of coinfections is a major threat to the patients. Although still in a low number, due to the short time of the pandemic, studies that identified a significant number of hospitalised patients with COVID-19 who developed secondary fungal infections that led to serious complications and even death have been published. OBJECTIVES: In this scenario, we aim to determine the prevalence of invasive fungal infections (IFIs) and describe possible associated risk factors in patients admitted due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. PATIENTS/METHODS: We designed an open prospective observational study at the Rey Juan Carlos University Hospital (Mostoles, Spain), during the period from February 1 to April 30, 2020. RESULTS: In this article, we reported seven patients with COVID-19-associated pulmonary aspergillosis (CAPA) who had a poor prognosis. Severely ill patients represent a high-risk group; therefore, we must actively investigate the possibility of aspergillosis in all of these patients. Larger cohort studies are needed to unravel the role of COVID-19 immunosuppressive therapy as a risk factor for aspergillosis. CONCLUSIONS: As the pandemic continues to spread across the world, further reports are needed to assess the frequency of emergent and highly resistant reemergent fungal infections during severe COVID-19. These coinfections are leading a significant number of patients with COVID-19 to death due to complications following the primary viral disease.


Assuntos
COVID-19/complicações , Aspergilose Pulmonar Invasiva/etiologia , Infecções Oportunistas/microbiologia , Adulto , Idoso , Aspergillus/genética , Aspergillus/isolamento & purificação , Aspergillus/fisiologia , COVID-19/virologia , Feminino , Hospitalização , Humanos , Instituições para Cuidados Intermediários/estatística & dados numéricos , Aspergilose Pulmonar Invasiva/microbiologia , Masculino , Pessoa de Meia-Idade , Infecções Oportunistas/etiologia , Prevalência , Estudos Prospectivos , SARS-CoV-2/fisiologia , Espanha
4.
Arch Bronconeumol ; 53(12): 667-674, 2017 Dec.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28647305

RESUMO

INTRODUCTION: Sexual limitations play an important role in the quality of life of patients with chronic diseases. Very limited information is available on the impact of asthma on the sexual functioning of these individuals. MATERIALS AND METHODS: Cross-sectional, observational, multicenter study. Asthma patients and healthy individuals were recruited. All subjects participated in an interview in which demographic and clinical data were recorded, and completed the Goldberg Anxiety-Depression Scale (GADS) to evaluate the presence of concomitant psychiatric disease. Men also completed the International Index of Erectile Function (IIEF), and women, the Female Sexual Function Index (FSFI). RESULTS: A total of 276cases were included, comprising 172asthma patients (63 men and 109 women) with a mean age of 42 (±14) years, and 104 controls (52men and 51women) with a mean age of 39 (±12) years. Time since onset of asthma was 15 years and severity distribution was: 6.4% intermittent, 17.9% mild persistent, 47.4% moderate, and 28.2% severe. Disease was considered controlled in 57.7%, partially controlled in 28.2%, and uncontrolled in 14.1%. Women with asthma had greater sexual limitations than women in the control group, with a total FSFI score of 22.1 (±9) compared to 26.5 (±6.8), respectively (P<.005). Men with asthma had significantly more severe erectile dysfunction with a total IIEF score of 59.5 (±12.5) compared to 64.3 (±8.2) in male controls (P<.05). An association was also observed between sexual problems and poorer asthma control. CONCLUSIONS: Asthma is associated with a poorer sexual quality of life among patients. These results should arouse the interest of healthcare professionals in detecting and alleviating possible sexual limitations among their asthma patients in routine clinical practice.


Assuntos
Asma/epidemiologia , Disfunções Sexuais Fisiológicas/epidemiologia , Adulto , Ansiedade/epidemiologia , Nível de Alerta , Asma/etiologia , Asma/fisiopatologia , Asma/psicologia , Estudos de Casos e Controles , Comorbidade , Estudos Transversais , Depressão/epidemiologia , Progressão da Doença , Disfunção Erétil/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Esforço Físico , Qualidade de Vida , Rinite/epidemiologia , Índice de Gravidade de Doença , Disfunções Sexuais Fisiológicas/fisiopatologia , Fumar/epidemiologia , Fumar/fisiopatologia , Espirometria
5.
Arch Bronconeumol ; 49(7): 289-96, 2013 Jul.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-23566766

RESUMO

BACKGROUND: Asthma guidelines recommend the adoption of allergen avoidance measures (AAM). To do so, patients need to know their own allergies. However, this degree of knowledge has not yet been assessed. The aims of this study were to determine, in allergic asthma patients: i)the degree of knowledge of their own allergic sensitizations; ii)the percentage of those who knew all their allergies and, in addition, adopted AAM against all of them, and iii)the possible impact of this degree of knowledge on the level of asthma control. PATIENTS AND METHODS: Descriptive, prospective and multicentre study, including 147patients from 9 Respiratory Medicine outpatient clinics. After confirming the previous allergic asthma diagnosis, a questionnaire was completed. It included asthma control and severity levels, results of previous allergy tests, and the description and number of allergic sensitizations known by the patients and AAM followed. RESULTS: Only 72 (49%) patients knew all their allergic sensitizations and only 48 (33%) were also following AAM against all the allergens to which they were allergic. No relationship was established between the degree of knowledge of their own allergies and the level of asthma control (P=.544). CONCLUSIONS: Overall knowledge about the allergic nature of their disease among asthmatic patients attending Spanish Respiratory Medicine Departments is inadequate. Furthermore, a higher degree of knowledge of their allergies does not seem to lead, by itself, to better asthma control. Both findings seem to question the effectiveness of current educational strategies in this field and consequently, they should be revised.


Assuntos
Alérgenos/efeitos adversos , Asma/psicologia , Conhecimentos, Atitudes e Prática em Saúde , Hipersensibilidade/psicologia , Pacientes Ambulatoriais/psicologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antialérgicos/uso terapêutico , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Asma/etiologia , Asma/prevenção & controle , Escolaridade , Feminino , Humanos , Hipersensibilidade/complicações , Masculino , Pessoa de Meia-Idade , Ambulatório Hospitalar , Educação de Pacientes como Assunto , Conhecimento do Paciente sobre a Medicação , Estudos Prospectivos , Pneumologia , Espanha , Inquéritos e Questionários , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA